{"id":97699,"date":"2025-09-08T08:35:29","date_gmt":"2025-09-08T06:35:29","guid":{"rendered":"https:\/\/www.formycon.com\/?page_id=97699"},"modified":"2026-03-20T10:56:38","modified_gmt":"2026-03-20T09:56:38","slug":"fyb201-ranibizumab","status":"publish","type":"page","link":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/","title":{"rendered":"FYB201 Ranibizumab"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; equal_height=&#8221;yes&#8221; gutter_size=&#8221;0&#8243; shift_y=&#8221;0&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;2&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_custom_heading text_color=&#8221;color-155072&#8243; heading_semantic=&#8221;h1&#8243; text_size=&#8221;h5&#8243; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; uncode_shortcode_id=&#8221;123207&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB201[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;135982&#8243; text_color_type=&#8221;uncode-palette&#8221;]Ranibizumab Biosimilar[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;h3&#8243; text_weight=&#8221;300&#8243; text_height=&#8221;fontheight-357766&#8243; uncode_shortcode_id=&#8221;118933&#8243;]The Lucentis\u00ae Biosimilar FYB201 is currently available as a treatment option for patients with severe retinal diseases in 24 countries worldwide. Additional product launches \u2013 including in Latin America and on the African continent \u2013 are to follow.[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;585328&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;134115&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_single_image media=&#8221;97784&#8243; media_width_use_pixel=&#8221;yes&#8221; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;211859&#8243; media_width_pixel=&#8221;1400&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;0&#8243; back_image=&#8221;97784&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;609407&#8243; row_height_pixel=&#8221;300&#8243;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;518395&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;762269&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;755974&#8243; column_width_pixel=&#8221;1200&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;832377&#8243;]<strong>Indication Area<br \/>\n<\/strong>Ophthalmology[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;196741&#8243;]<strong>Active Ingredient Group<br \/>\n<\/strong>VEGF\u00a0inhibitors[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;622265&#8243;]<strong>Indications of the Reference Drug<br \/>\n<\/strong>Neovascular (\u201cwet\u201d) age-related macular degeneration (nAMD),\u00a0 Diabetic macular edema (DME), Choroidal neovascularization (CNV), Proliferative diabetic retinopathy (PDR), Macular edema following retinal vein occlusion (RVO)*[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;273392&#8243;]<strong>Market Launch<br \/>\n<\/strong>2022<strong><br \/>\n<\/strong>[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;959900&#8243;]<strong>Business Modell:<br \/>\n<\/strong>50% Formycon project via the stake in Bioeq AG, a joint venture of Formycon AG and Polpharma Biologics Group B.V.<strong><br \/>\n<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;127637&#8243;]<strong>Ranibizumab Market<\/strong><br \/>\nRanibizumab is one of the standard anti-VEGF therapies. In 2025, the reference drug Lucentis\u00ae generated global sales of approximately $600 million.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;205982&#8243; el_width=&#8221;100%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;152107&#8243;]<strong>Commercialization partners:<\/strong>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;141105&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97807 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Teva_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brands:<\/strong> Ranivisio\u00ae, Ongavia\u00ae, Ranopto\u00ae<br \/>\n<strong>Region:<\/strong> EU, UK, Canada[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;474119&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97805 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Sandoz_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brands:<\/strong> Cimerli\u00ae, Epruvy\u00ae<br \/>\n<strong>Region:<\/strong> US, Germany[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;535565&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-99204 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2026\/02\/Zydus_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brands:<\/strong> Nufymco<strong>\u00ae<\/strong><br \/>\n<strong>Region:<\/strong> US[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;749963&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97801 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/MSPharma_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brands:<\/strong> Ravegza\u00ae, Uptera\u00ae<br \/>\n<strong>Region:<\/strong> MENA[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;157891&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97791 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/BioUsawa_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brands:<\/strong> BioUcenta<br \/>\n<strong>Region:<\/strong> Sub-saharan Afrika[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;967612&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97789 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Biomm_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brands:<\/strong> Ranivisio\u00ae<br \/>\n<strong>Region:<\/strong> Brazil[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; position_vertical=&#8221;bottom&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183068&#8243;][vc_separator sep_color=&#8221;&#8221; uncode_shortcode_id=&#8221;149492&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;918267&#8243;]<\/p>\n<div style=\"text-align: right;\">* \u00a0The specific indication groups approved are listed in the product information<br \/>\nprovided by the EMA or FDA.<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;118803&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;97724&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;189665&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;202553&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_empty_space empty_h=&#8221;4&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;458872&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB201 Biosimilar Development[\/vc_custom_heading][vc_empty_space empty_h=&#8221;4&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;447782&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;97835&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;491567&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;801105&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_size=&#8221;h4&#8243; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;194055&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB201 Biosimilar Development[\/vc_custom_heading][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;185374&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;102763&#8243; column_width_pixel=&#8221;800&#8243;][vc_empty_space empty_h=&#8221;3&#8243; mobile_visibility=&#8221;yes&#8221;][vc_accordion typography=&#8221;yes&#8221; gutter_simple=&#8221;0&#8243; uncode_shortcode_id=&#8221;605931&#8243; el_id=&#8221;devdetails&#8221; el_class=&#8221;devdetails&#8221; active_tab=&#8221;0&#8243;][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;FYB201 (Ranibizumab) Mode of Action&#8221; tab_id=&#8221;1730916296154-2-101744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183589&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; subheading=&#8221;FYB201\/Ranibizumab is a monoclonal antibody that is applied to treat adults with visual impairment due to damage to the retina, particularly the macula. The macula is important for the vision needed for everyday activities such as driving, reading and recognizing faces.<\/p>\n<p>The antibody binds to vascular endothelial growth factor A (VEGF-A), which triggers the growth of blood vessels and leads to the leakage of fluid and blood. This is the cause of severe damage to the macula. By blocking VEGF-A, ranibizumab reduces the growth of blood vessels, fluid leakage and swelling.&#8221; uncode_shortcode_id=&#8221;165737&#8243; heading_custom_size=&#8221;24px&#8221; text_color_type=&#8221;uncode-palette&#8221; text_color_solid=&#8221;#ff0000&#8243;]This is how FYB201 (ranibizumab) works[\/vc_custom_heading][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;149278&#8243;]<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.ema.europa.eu\/de\/documents\/product-information\/ranivisio-epar-product-information_de.pdf\" target=\"_blank\" rel=\"noopener\">Further information<\/a><\/p>\n<p>[\/vc_column_text][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Development and Commercialization Milestones&#8221; tab_id=&#8221;1730790947-1-351744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;188630&#8243;][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;358050&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Nufymco<sup>\u00ae<\/sup> approved by the FDA; Zydus becomes commercialization partner<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fda-approves-another-interchangeable-ranibizumab-biosimilar-nufymco-strengthening-us-presence-with-zydus-as-commercialization-partner\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;110688&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">November 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Epruvy<sup>\u00ae<\/sup> launched in Germany<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/ranibizumab-biosimilar-epruvy-launched-in-germany\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;210077&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">October 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Ranivisio<sup>\u00ae<\/sup> is the first Lucentis<sup>\u00ae<\/sup>\u00a0biosimilar in Europe to be offered as a pre-filled syringe<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/bio-usawa-becomes-partner-for-the-commercialization-of-fyb201-bioucenta-ranibizumab-across-sub-saharan-africa\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;811786&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">July 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Bio Usawa becomes partner for the commercialization of FYB201\/BioUcenta\u2122 across Sub-Saharan Africa<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/bio-usawa-becomes-partner-for-the-commercialization-of-fyb201-bioucenta-ranibizumab-across-sub-saharan-africa\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;367620&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">June 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Approval in Brazil<br \/>\n<\/span><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/lucentis-biosimilar-fyb201-ranivisio-ranibizumab-approved-in-brazil\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;172370&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">April 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Commercial Launch in Canada and Switzerland<br \/>\n<\/span><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fyb201-launch-ca-and-ch\/\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;356227&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Approvals and Launches in the MENA Region<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fyb201-ranibizumab-keeps-gaining-momentum-with-approvals-and-launches-in-the-mena-region\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;203544&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Sandoz\u00a0 Inc. replaces Coherus BioSciences as commercialization partner for the US<\/span>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;141491&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">January 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB201\/CIMERLI\u00ae achieved a market share of 38% in the United States in December 2023<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fyb201-us-uptake-dec2023\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;204356&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Approval in Canada<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/canada-approval-fyb201\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;819792&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">October 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB201\/CIMERLI\u00ae achieved 25% market share\u00a0in the United States<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/25-percent-market-share-for-fyb201-in-the-us\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;393263&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">August 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB201 approved by the European Commission<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/european-commission-approves-fyb201-ranivisio1-ranivisio-ranibizumab-a-biosimilar-to-lucentis2\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;180046&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">August 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB201 approved by the FDA as interchangeable biosimilar<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/u-s-food-and-drug-administration-fda-approved-fyb201-cimerlitm1-ranibizumab-eqrn-the-first-and-only-biosimilar-interchangeable-with-lucentis2\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;818597&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">June 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB201 receives CHMP recommendation from EMA<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fyb201-formycons-biosimilar-for-lucentis-ranibizumab-receives-chmp-recommendation-from-ema\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;101778&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">May 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Approval in UK<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/united-kingdom-medicines-and-healthcare-products-regulatory-agency-mhra-grants-marketing-authorization-for-fyb201-formycons-biosimilar-for-lucentis1-to-be-commercialized-by-teva-as-ongavia\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;973924&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">May 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Transaction with ATHOS KG to acquire the biosimilar assets FYB201 and FYB202<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-ag-and-athos-kg-announce-closing-of-transaction-to-acquire-biosimilar-assets-fyb201-and-fyb202-as-well-as-bioeq-gmbh\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;173385&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2021<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">MS Pharma becomes Partner for the Commercialization of FYB201 in the MENA Region<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/ms-pharma-becomes-partner-for-the-commercialization-of-fyb201-formycons-biosimilar-candidate-to-lucentisr1-ranibizumab-in-the-mena-region\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;339562&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">October 2021<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FDA accepts the biologics license application (BLA) for FYB201<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-bioeq-announce-file-acceptance-for-fyb201-a-biosimilar-candidate-to-lucentis-ranibizumab-by-the-u-s-food-and-drug-administration-fda\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;386440&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">August 2021<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Submission of the biologics license application (BLA) to the U.S. Food and Drug Administration (FDA)<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-bioeq-announce-submission-of-the-biologics-license-application-bla-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-u-s-food-and-drug-administration-fda\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;375264&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">June 2021<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Submission of the marketing authorization application to the European Medicines Agency (EMA)<br \/>\n<\/span><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-bioeq-announce-submission-of-the-marketing-authorization-application-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-european-medicines-agency-ema\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;389964&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">June 2021<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Teva becomes strategic partner for the commercialization of FYB201 in Europe, Canada, Israel and New Zealand<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/teva-pharmaceutical-industries-ltd-becomes-strategic-partner-for-the-commercialization-of-fyb201-formycons-biosimilar-candidate-to-lucentisr1-ranibizumab-in-europe-canada-israel-and-new-zeala\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;981848&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">November 2019<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Coherus BioSciences becomes Commercialization Partner for the U.S.<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/bioeq-ip-ag-exclusively-licenses-us-marketing-rights-for-fyb201-to-coherus-biosciences-inc\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;931168&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">May 2018<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Successful completion of Phase III study<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-bioeq-achieve-important-milestone-biosimilar-ranibizumab-candidate-fyb201-shows-efficacy-comparable-to-the-reference-product-in-phase-iii-study\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;124166&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2016<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Start of clinical Phase III study (First Patient-In)<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-bioeq-enroll-first-patient-in-pivotal-phase-iii-study-with-biosimilar-ranibizumab-fyb201\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;975482&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2015<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Successful GMP inspection in Martinsried<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-ag-announces-successful-gmp-inspection-and-the-start-of-us-fda-scientific-advice-procedure-for-its-out-licensed-biosimilar-fyb201\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Scientific Publications on FYB201&#8243; tab_id=&#8221;1730790947-2-501744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;693360&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; uncode_shortcode_id=&#8221;665703&#8243; heading_custom_size=&#8221;24px&#8221;]Clinical data from the Phase III efficacy study[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][vc_gallery el_id=&#8221;gallery-130684&#8243; type=&#8221;carousel&#8221; medias=&#8221;97845,97767,97765&#8243; carousel_lg=&#8221;3&#8243; carousel_md=&#8221;2&#8243; carousel_sm=&#8221;1&#8243; gutter_size=&#8221;3&#8243; media_items=&#8221;media|custom_link|original,description,icon,caption&#8221; carousel_interval=&#8221;3000&#8243; carousel_navspeed=&#8221;400&#8243; carousel_loop=&#8221;yes&#8221; stage_padding=&#8221;0&#8243; single_overlay_opacity=&#8221;50&#8243; single_padding=&#8221;2&#8243; uncode_shortcode_id=&#8221;165348&#8243; single_link=&#8221;url:https%3A%2F%2Fwww.formycon.com%2Funternehmen%2Fkontakt%2F|title:Kontakt&#8221; items=&#8221;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&#8221;][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;762269&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;755974&#8243; column_width_pixel=&#8221;1200&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; limit_content=&#8221;&#8221; uncode_shortcode_id=&#8221;149764&#8243; css=&#8221;.vc_custom_1757693219486{padding-right: 112px !important;}&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; position_vertical=&#8221;bottom&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183068&#8243;][vc_empty_space empty_h=&#8221;2&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;191096&#8243;]<\/p>\n<div style=\"text-align: right;\">Lucentis\u00ae is a registered trademark of Genentech, Inc.<br \/>\nRanivisio\u00ae is a registered trademark of Bioeq AG \u00b7 Ranopto\u2122 is a trademark of Teva Canada Limited<\/div>\n<div style=\"text-align: right;\">ONGAVIA\u00ae is a registered trademark of Teva Pharmaceutical Industries Ltd.<\/div>\n<div style=\"text-align: right;\">CIMERLI\u00aeand Epruvy\u00ae are registered trademarks of Sandoz, Inc.<br \/>\nRavegza\u00ae and Uptera\u00ae are registered trademarks of MS Pharma<\/div>\n<div style=\"text-align: right;\">BioUcenta\u2122 is a\u00a0 trademark of Bio Usawa Biotechnology Ltd.<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]<\/p>\n","protected":false},"author":23,"featured_media":80989,"parent":78082,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-97699","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FYB201 Ranibizumab - Formycon AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FYB201 Ranibizumab - Formycon AG\" \/>\n<meta property=\"og:description\" content=\"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Formycon AG\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T09:56:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb201-formycon-keyvisual.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/\",\"url\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/\",\"name\":\"FYB201 Ranibizumab - Formycon AG\",\"isPartOf\":{\"@id\":\"https:\/\/www.formycon.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb201-formycon-keyvisual.jpg\",\"datePublished\":\"2025-09-08T06:35:29+00:00\",\"dateModified\":\"2026-03-20T09:56:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#primaryimage\",\"url\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb201-formycon-keyvisual.jpg\",\"contentUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb201-formycon-keyvisual.jpg\",\"width\":1600,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.formycon.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars\",\"item\":\"https:\/\/www.formycon.com\/en\/biosimilars\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FYB201 Ranibizumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.formycon.com\/en\/#website\",\"url\":\"https:\/\/www.formycon.com\/en\/\",\"name\":\"Formycon AG\",\"description\":\"Global Quality Biosimilars\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.formycon.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FYB201 Ranibizumab - Formycon AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/","og_locale":"en_US","og_type":"article","og_title":"FYB201 Ranibizumab - Formycon AG","og_description":"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]","og_url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/","og_site_name":"Formycon AG","article_modified_time":"2026-03-20T09:56:38+00:00","og_image":[{"width":1600,"height":800,"url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb201-formycon-keyvisual.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/","url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/","name":"FYB201 Ranibizumab - Formycon AG","isPartOf":{"@id":"https:\/\/www.formycon.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#primaryimage"},"image":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb201-formycon-keyvisual.jpg","datePublished":"2025-09-08T06:35:29+00:00","dateModified":"2026-03-20T09:56:38+00:00","breadcrumb":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/"]}]},{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#primaryimage","url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb201-formycon-keyvisual.jpg","contentUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb201-formycon-keyvisual.jpg","width":1600,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb201-ranibizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.formycon.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biosimilars","item":"https:\/\/www.formycon.com\/en\/biosimilars\/"},{"@type":"ListItem","position":3,"name":"FYB201 Ranibizumab"}]},{"@type":"WebSite","@id":"https:\/\/www.formycon.com\/en\/#website","url":"https:\/\/www.formycon.com\/en\/","name":"Formycon AG","description":"Global Quality Biosimilars","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.formycon.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-25 12:40:22","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/comments?post=97699"}],"version-history":[{"count":5,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97699\/revisions"}],"predecessor-version":[{"id":99363,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97699\/revisions\/99363"}],"up":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media\/80989"}],"wp:attachment":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media?parent=97699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}